Development of Sanofi Pasteur tetravalent dengue vaccine

被引:5
|
作者
Guy, Bruno [1 ]
Saville, Melanie
Lang, Jean
机构
[1] Sanofi Pasteur, Dept Res, Marcy Letoile, France
来源
HUMAN VACCINES | 2010年 / 6卷 / 09期
关键词
dengue; vaccine; human; development; immunity; YELLOW-FEVER VIRUS; ANTIBODY-DEPENDENT ENHANCEMENT; LIVE FLAVIVIRUS VACCINES; HUMAN DENDRITIC CELLS; HEMORRHAGIC-FEVER; NONHUMAN-PRIMATES; AEDES-AEGYPTI; INFECTION; SEROTYPES; SAFETY;
D O I
10.4161/hv.6.9.12739
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The Sanofi Pasteur tetravalent dengue vaccine candidate is composed of 4 recombinant live attenuated vaccines based on a yellow fever vaccine 17D (YFV 17D) backbone, each expressing the prM and envelope genes of one of the four dengue virus serotypes. Pre-clinical studies have demonstrated that the TV dengue vaccine is genetically and phenotypically stable, non-hepatotropic, less neurovirulent than YFV 17D and does not infect mosquitoes by the oral route. In vitro and in vivo preclinical studies also showed that the TV dengue vaccine induced controlled stimulation in human dendritic cells and significant immune responses in monkeys. TV dengue vaccine reactogenicity, viraemia induction and antibody responses were investigated in three Phase I trials in the USA, the Philippines and Mexico, in a two or three-dose regimen over a 12 month period. Results showed that the majority of adverse events were mild to moderate and transient in nature. Viraemia was transient and low, and was not increased after initial dengue TV administration, even in the case of incomplete responses. Phi Seropositivity [>= 10 in a PRNT 50 assay] was 100% for all four serotypes in flavivirus-naive adults injected with 3 doses of TV dengue vaccine in the USA. Similarly, seropositivity was 88-100% following three administrations in flavivirus-naive Mexican children aged 2-5 years. Furthermore, the proportion of seropositive subjects increased with each dengue TV injection in the Philippines where baseline flavivirus immunity was high. Responses were also monitored at the cellular level in humans, and their level and nature were in good agreement with the observed safety and the immunogenicity of the vaccine. Finally, the challenges inherent to the development of such TV dengue vaccines will also be discussed in the last part of this review. In conclusion, preclinical and clinical results support the favorable immunogenicity and short-term safety of the dengue TV vaccine. An extensive clinical development program for dengue TV is underway including completion of the enrollment of 4,000 4-11 years old children in an efficacy trial in Thailand, in an area of high dengue incidence. Assuming continued successful outcomes, initial submissions to regulatory authorities are envisaged within a 5-year period.
引用
收藏
页码:696 / 705
页数:10
相关论文
共 50 条
  • [1] DEVELOPMENT OF SANOFI PASTEUR TETRAVALENT DENGUE VACCINE
    Lang, Jean
    [J]. REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2012, 54 : S15 - S17
  • [2] Immunogenicity of sanofi pasteur tetravalent dengue vaccine
    Guy, Bruno
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2009, 46 : S16 - S19
  • [3] Preclinical and clinical development of Sanofi Pasteur recombinant tetravalent dengue vaccine
    Plennevaux, E.
    Viviani, S.
    Guy, B.
    Lang, J.
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 : 235 - 235
  • [4] Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward
    Guy, Bruno
    Briand, Olivier
    Lang, Jean
    Saville, Melanie
    Jackson, Nicholas
    [J]. VACCINE, 2015, 33 (50) : 7100 - 7111
  • [5] UPDATE ON THE PHASE III STAGE SANOFI PASTEUR RECOMBINANT TETRAVALENT DENGUE VACCINE
    Lang, Jean
    Saville, Melanie
    Guy, Bruno
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 83 (05): : 29 - 29
  • [6] DEVELOPMENT OF SANOFI PASTEUR'S RECOMBINANT LIVE-ATTENUATED TETRAVALENT DENGUE VACCINE: 2009 UPDATE
    Dumas, Rafaela
    Saville, Melanie
    Guy, Bruno
    Lang, Jean
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 81 (05): : 125 - 125
  • [7] From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
    Guy, Bruno
    Barrere, Beatrice
    Malinowski, Claire
    Saville, Melanie
    Teyssou, Remy
    Lang, Jean
    [J]. VACCINE, 2011, 29 (42) : 7229 - 7241
  • [8] Toxicity, biodistribution and shedding of Sanofi Pasteur live, attenuated, tetravalent, dengue vaccine in cynomolgus monkeys
    Ravel, G.
    Mantel, N.
    Lang, J.
    Gould, S.
    [J]. TOXICOLOGY LETTERS, 2011, 205 : S244 - S244
  • [9] Safety, Viremia and Immunogenicity of Sanofi Pasteur Tetravalent Dengue Vaccine in Adults Previously Exposed to Live, Attenuated Flaviviruses
    Qiao, M.
    Shaw, D.
    Forrat, R.
    Wartel-Tram, A.
    Lang, J.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E144 - E145
  • [10] Proof of efficacy shown for Sanofi Pasteur's dengue vaccine
    Riedmann, Eva M.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (09) : 1168 - 1168